Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologyFRA:XE7C +5.23%26 Cyclically Adjusted PB Ratio is 0.11 as of Aug. 25, 2026, which is 8% below its 10-year median of 0.12. GuruFocus rates FRA:XE7C with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 685 Biotechnology companies, Cardiff Oncology ranks better than 87.3% on this metric.
The historical rank and industry rank for Cardiff Oncology's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:XE7C'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.03 Med: 0.12 Max: 0.7
Current: 0.13
During the past years, Cardiff Oncology's highest Cyclically Adjusted PB Ratio was 0.70. The lowest was 0.03. And the median was 0.12.
FRA:XE7C's Cyclically Adjusted PB Ratio is ranked better than 87.3% of 685
companies
in the Biotechnology industry
Industry Median: 1.62
vs FRA:XE7C: 0.13
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Cardiff Oncology's adjusted book value per share data for the three months ended in Jun. 2026 was €0.336. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €6.07 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Cardiff Oncology (FRA:XE7C) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Cardiff Oncology Cyclically Adjusted PB Ratio Related Terms
Cardiff Oncology Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology Cyclically Adjusted PB Ratio Chart
FRA:XE7C vs MNOV, PMVP, CING: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted PB Ratio falls into.
Cardiff Oncology Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Cardiff Oncology's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.11 mean?
Cardiff Oncology (FRA:XE7C) has a Cyclically Adjusted PB Ratio of 0.11 as of Aug. 25, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Cardiff Oncology and its competitors. This is near median its historical median of 0.12. Over the past decade, Cardiff Oncology's Cyclically Adjusted PB Ratio has ranged from 0.03 to 0.70. According to the industry distribution chart, Cardiff Oncology ranks #87 out of 685 companies in the Biotechnology industry, placing it in the top 12.7%.
Is Cardiff Oncology's Cyclically Adjusted PB Ratio too high?
Cardiff Oncology's current Cyclically Adjusted PB Ratio of 0.11 is near median its 10-year median of 0.12. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.70. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.62. Cardiff Oncology's value of 0.11 is 93.2% below this industry median. Based on the distribution chart, Cardiff Oncology ranks #87 out of 685 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardiff Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Cyclically Adjusted PB Ratio compare to MNOV and PMVP?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #87 out of 685 companies for Cyclically Adjusted PB Ratio. This places Cardiff Oncology in the top 13% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PB Ratio is 1.62. Cardiff Oncology's value of 0.11 is 93.2% below this benchmark. Historically, Cardiff Oncology's own Cyclically Adjusted PB Ratio has ranged from 0.03 to 0.70 over the past decade. While the company's 10-year median is 0.12 vs. the industry median of 1.62, Cardiff Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.62, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Cyclically Adjusted PB Ratio of 0.11 is 93.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Cyclically Adjusted PB Ratio is 0.11, which is near median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (FRA:XE7C) has a current Cyclically Adjusted PB Ratio of 0.11. The current Cyclically Adjusted PB Ratio is 0.11, which is near median its 10-year median of 0.12 and 93.2% below the Biotechnology industry median of 1.62. Cardiff Oncology's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Cardiff Oncology (FRA:XE7C), the current Cyclically Adjusted PB Ratio is 0.11 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
26GF Score
Get the complete analysis for FRA:XE7C
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XE7C has been successfully added to your 
